Skip to content
cobicistat

Structure via PubChem · Public domain (PubChem)

EntityQ5138908· pop 20· linked from 135 articles

cobicistat

Sign in to save

Also known as GS-9350, GS 9350, 1,3-thiazol-5-ylmethyl [(2R,5R)-5-{[(2S)-2-({[(2-isopropyl-1,3-thiazol-4-yl)methyl](methyl)carbamoyl}amino)-4-(morpholin-4-yl)butanoyl]amino}-1,6-diphenylhexan-2-yl]carbamate

Cobicistat, sold under the brand name Tybost, is a medication for use in the treatment of human immunodeficiency virus infection (HIV/AIDS). Its major mechanism of action is through the inhibition of human CYP3A proteins.

Chemical data

Formula
C40H53N7O5S2
Molecular weight
776 g/mol
IUPAC name
1,3-thiazol-5-ylmethyl N-[(2R,5R)-5-[[(2S)-2-[[methyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]-4-morpholin-4-ylbutanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate
SMILES
CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5
InChIKey
ZCIGNRJZKPOIKD-CQXVEOKZSA-N
XLogP
5.7
Polar surface area
195 Ų
H-bond donors
3
H-bond acceptors
10
Formal charge
0

via PubChem

~6 min read

Encyclopedic overview

4 sections
Contents
  • Chemistry
  • Synthesis
  • Discovery and development
  • References

{{Drugbox | Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 451564721 | IUPAC_name = 1,3-thiazol-5-ylmethyl [(2R,5R)-5-{[(2S)-2-[(methyl{[2-(propan-2-yl)-1,3-thiazol-4-yl]methyl}carbamoyl)amino]-4-(morpholin-4-yl)butanoyl]amino}-1,6-diphenylhexan-2-yl]carbamate | image = Cobicistat structure.svg | image_class = skin-invert-image | width = 275 | drug_name =

| pronounce = | tradename = Tybost | Drugs.com = | MedlinePlus = a616029 | licence_EU = yes | licence_US = | DailyMedID = Cobicistat | pregnancy_AU = | pregnancy_US = | pregnancy_category = | legal_AU = | legal_CA = | legal_UK = | legal_US = Rx-only | legal_status = | dependency_liability = | routes_of_administration = | ATC_prefix = V03 | ATC_suffix = AX03 | ATC_supplemental =

Excerpted from Wikipedia’s “cobicistat” article, available under the CC BY-SA 4.0 licence.